Sponsor: Seattle Genetics, Inc.
Sponsor Study ID: SGN35-031
Study Title: A Randomized, Double blind, Placebo Controlled, Active Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B cell Lymphoma (DLBCL)
CTO #: 103233
NCT Number: NCT04404283
Phase: III
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Non-Hodgkin's Lymphoma
Study Objectives: This study is being done to see if adding brentuximab vedotin helps two drugs work better to treat patients with diffuse large B-cell lymphoma (DLBCL). Participants in this study will have DLBCL that has come back or not gotten better with treatment.